Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
CZP 200 mg Q2W
BIOLOGICAL
2 trials
Sponsors
UCB BIOSCIENCES GmbH
Conditions
Arthritis, Psoriatic
Spondyloarthropathies
Phase 3
Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis
Completed
NCT01087788
UCB BIOSCIENCES GmbH
Arthritis, Psoriatic
Start: 2010-03-31
End: 2015-08-31
Updated: 2018-08-01
Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis
Completed
NCT01087762
UCB BIOSCIENCES GmbH
Spondyloarthropathies
Start: 2010-03-31
End: 2015-08-31
Updated: 2018-08-01
Related Papers
Performance analysis of a deep-learning algorithm to detect the presence of inflammation in MRI of sacroiliac joints in patients with axial spondyloarthritis.
2025-01-02
6 citations
Machine learning <i>vs</i> human experts: sacroiliitis analysis from the RAPID-axSpA and C-OPTIMISE phase 3 axSpA trials
Rheumatology Advances in Practice
2025-01-01
1 citations
Exploratory analysis of the potential disconnect between objective inflammatory response and clinical response following certolizumab pegol treatment in patients with active axial spondyloarthritis
RMD Open
2024-08-01
3 citations
Achievement of higher thresholds of clinical responses and lower levels of disease activity is associated with improvements in workplace and household productivity in patients with axial spondyloarthritis
Therapeutic Advances in Musculoskeletal Disease
2023-01-01
2 citations
Certolizumab pegol treatment in axial spondyloarthritis mitigates fat lesion development: 4-year post-hoc MRI results from a phase 3 study
Lara D. Veeken
2021-11-11
5 citations
Validation of the Ankylosing Spondylitis Quality of Life assessment tool in patients with non-radiographic axial spondyloarthritis.
2020-10-31
9 citations
Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISE
Rheumatology and Therapy
2020-06-11
18 citations
A single determination of C-reactive protein does not suffice to declare a patient with a diagnosis of axial spondyloarthritis 'CRP-negative'.
2018-09-14
20 citations
Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial.
2018-09-06
12 citations
PGA×BSA: A Measure of Psoriasis Severity Tested in Patients with Active Psoriatic Arthritis and Treated with Certolizumab Pegol.
2018-05-01
8 citations
Improvements in workplace and household productivity with certolizumab pegol treatment in axial spondyloarthritis: results to week 96 of a phase III study
RMD Open
2018-04-01
14 citations
162 Efficacyand safety of certolizumab pegol over four years in psoriatic arthritis patientswith and without concomitant use of DMARDs
Lara D. Veeken
2018-04-01
4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis.
2018-03-14
23 citations
Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial
Annals of the Rheumatic Diseases
2018-01-17
128 citations
Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation
Annals of the Rheumatic Diseases
2017-12-23
249 citations
Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA
Lara D. Veeken
2017-04-05
94 citations
Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis
RMD Open
2017-04-01
37 citations
Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis.
2016-06-01
64 citations
Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure
RMD Open
2015-06-01
45 citations
Are patient-reported outcome instruments for ankylosing spondylitis fit for purpose for the axial spondyloarthritis patient? A qualitative and psychometric analysis.
2015-05-21
20 citations
8 more papers not shown